Current Treatments and Innovations in Diabetic Retinopathy and Diabetic Macular Edema

González-Cortés, Jesús Hernán; Martinez-Pacheco, Victor A.; Gonzalez-Cantu, Jesus Emiliano; Bilgic, Alper; Ribot, Francesc March de; Sudhalkar, Aditya; Mohamed-Hamsho, Jesús; Kodjikian, Laurent; Mathis, Thibaud

doi:10.3390/pharmaceutics15010122

Cited by 25 publications

(12 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 12 , 13 In terms of pathophysiology, corticosteroids can inhibit the production of pro-inflammatory mediators, reduce VEGF synthesis indirectly, and decrease the loss of endothelial tension-binding proteins. 14 Besides reducing VEGF level, Conbercept treatment also significantly reduced some inflammatory factors, such as intercellular cell adhesion molecule-1 (ICAM-1), macrophage inflammatory protein-1 (MIP-1), IL-1β, IL-6 and TNF-α protein levels in aqueous fluid of PDR patients. 15 Ozurdex releases small amounts of corticosteroids in a time-dependent manner.…”

Section: Discussionmentioning

confidence: 99%

The Anatomic and Functional Outcomes of Ozurdex-Aided Vitrectomy in Proliferative Diabetic Retinopathy

Wang,

Luan,

Liu

et al. 2024

DMSO

View full text Add to dashboard Cite

Purpose To investigate the 3-months outcomes of patients who underwent intraoperative intravitreal injection of Ozurdex for proliferative diabetic retinopathy (PDR). Methods This is a prospective randomized controlled clinical trial (ChiCTR2100043399). Seventy-one patients with PDR who had indications for surgery without intravitreal injection history within 3 months preoperatively were enrolled. Patients were randomly divided into three groups based on the medicine injected intraoperatively: Ozurdex, Conbercept, and Control group. The primary outcome is the best-corrected visual acuity (BCVA) within 3 months postoperatively. The secondary outcomes include the intraocular pressure (IOP), mean sensitivity, central retinal thickness and vessels perfusion. Results The BCVA and the mean sensitivity improved in the three groups (F = 130.8, P < 0.0001; F = 34.18, P < 0.0001), but there was no statistical difference among the three groups (F = 0.858, P = 0.552; F = 0.964, P = 0.452). The IOP was no significant differences among the three groups within 3 months postoperatively (F = 0.881, P = 0.533). Compared with the other two groups, central retinal thickness (CRT) and outer retinal layer (ORL) thickness decreased significantly in patients of the Ozurdex group (F = 3.037, P = 0.008; F = 2.626, P = 0.018), especially in the diabetic macular edema (DME) patients (F = 2.761, P = 0.0164; F = 2.572, P = 0.0240). In macular region, superficial vascular plexus (SVP), intermediate capillary plexus (ICP) and deep capillary plexus (DCP) perfusion were not shown statistical difference at 3 months postoperatively in the all three groups compared with 1 day postoperatively (P > 0.05). Conclusion Compared with the other two groups, anatomical outcomes was improved significantly in Ozurdex group for DR patients. Ozurdex may help to improve the visual acuity and visual sensitivity, and there is no significant difference in the change of IOP and microvascular improvement. Clinical Trial Registration This trial is registered with the Chinese Clinical Trial Registry ( http://www.chictr.org.cn , registration number ChiCTR2100043399).

show abstract

Section: Discussionmentioning

confidence: 99%

The Anatomic and Functional Outcomes of Ozurdex-Aided Vitrectomy in Proliferative Diabetic Retinopathy

Wang,

Luan,

Liu

et al. 2024

DMSO

View full text Add to dashboard Cite

show abstract

“…Treatment modalities may involve administering medications directly into the eye, such as VEGF inhibitors, to impede the formation of new blood vessels and mitigate fluid accumulation. Additionally, laser treatment and surgical interventions may be recommended, tailored to address specific retinal complications [ 10 ]. Efforts geared toward prevention are integral to managing DR.…”

Section: Reviewmentioning

confidence: 99%

Understanding the Clinical Relationship Between Diabetic Retinopathy, Nephropathy, and Neuropathy: A Comprehensive Review

Kulkarni,

Thool,

Daigavane

2024

Cureus

View full text Add to dashboard Cite

Diabetic retinopathy, nephropathy, and neuropathy are significant microvascular complications of diabetes mellitus, contributing to substantial morbidity and mortality worldwide. This comprehensive review examines the clinical relationship between these complications, focusing on shared pathophysiological mechanisms, bidirectional relationships, and implications for patient management. The review highlights the importance of understanding the interconnected nature of diabetic complications and adopting a holistic approach to diabetes care. Insights gleaned from this review underscore the necessity for early detection, timely intervention, and integrated care models involving collaboration among healthcare professionals. Furthermore, the review emphasizes the need for continued research to elucidate underlying mechanisms, identify novel therapeutic targets, and assess the efficacy of integrated care strategies in improving patient outcomes. By fostering interdisciplinary collaboration and knowledge exchange, future research endeavors hold the potential to advance our understanding and management of diabetic complications, ultimately enhancing patient care and quality of life.

show abstract

“…A new prospective direction has also been developed in the therapy of diabetic retinopathy. There is a large number of new intravitreal anti-vascular endothelial growth factor injections [63], which are successfully used along with classical treatment methods (laser photocoagulation and vitreoretinal surgery).…”

Section: T1d Treatment Options and Complicationsmentioning

confidence: 99%

Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a “Trojan Horse”

Karpov,

Sosnovtseva,

Pylina

et al. 2023

IJMS

View full text Add to dashboard Cite

Type 1 diabetes mellitus (T1D) is an autoimmune disease caused by the destruction of insulin-producing β-cells in the pancreas by cytotoxic T-cells. To date, there are no drugs that can prevent the development of T1D. Insulin replacement therapy is the standard care for patients with T1D. This treatment is life-saving, but is expensive, can lead to acute and long-term complications, and results in reduced overall life expectancy. This has stimulated the research and development of alternative treatments for T1D. In this review, we consider potential therapies for T1D using cellular regenerative medicine approaches with a focus on CRISPR/Cas-engineered cellular products. However, CRISPR/Cas as a genome editing tool has several drawbacks that should be considered for safe and efficient cell engineering. In addition, cellular engineering approaches themselves pose a hidden threat. The purpose of this review is to critically discuss novel strategies for the treatment of T1D using genome editing technology. A well-designed approach to β-cell derivation using CRISPR/Cas-based genome editing technology will significantly reduce the risk of incorrectly engineered cell products that could behave as a “Trojan horse”.

show abstract

Current Treatments and Innovations in Diabetic Retinopathy and Diabetic Macular Edema

Cited by 25 publications

References 87 publications

The Anatomic and Functional Outcomes of Ozurdex-Aided Vitrectomy in Proliferative Diabetic Retinopathy

The Anatomic and Functional Outcomes of Ozurdex-Aided Vitrectomy in Proliferative Diabetic Retinopathy

Understanding the Clinical Relationship Between Diabetic Retinopathy, Nephropathy, and Neuropathy: A Comprehensive Review

Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a “Trojan Horse”

Contact Info

Product

Resources

About